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ABSTRACT: Background: There are currently no
treatments that stop or slow the progression of
Parkinson’s disease (PD). Case–control genome-wide
association studies have identified variants associated
with disease risk, but not progression. The objective of
the current study was to identify genetic variants associ-
ated with PD progression.
Methods: We analyzed 3 large longitudinal cohorts:
Tracking Parkinson’s, Oxford Discovery, and the
Parkinson’s Progression Markers Initiative. We included
clinical data for 3364 patients with 12,144 observations
(mean follow-up 4.2 years). We used a new method in
PD, following a similar approach in Huntington’s disease,
in which we combined multiple assessments using a
principal components analysis to derive scores for com-
posite, motor, and cognitive progression. These scores
were analyzed in linear regression in genome-wide asso-
ciation studies. We also performed a targeted analysis of
the 90 PD risk loci from the latest case–control meta-
analysis.
Results: There was no overlap between variants associ-
ated with PD risk, from case–control studies, and PD age
at onset versus PD progression. The APOE ε4 tagging
variant, rs429358, was significantly associated with com-
posite and cognitive progression in PD. Conditional anal-
ysis revealed several independent signals in the APOE
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locus for cognitive progression. No single variants were
associated with motor progression. However, in gene-
based analysis, ATP8B2, a phospholipid transporter
related to vesicle formation, was nominally associated
with motor progression (P = 5.3 × 10−6).
Conclusions: We provide early evidence that this new
method in PD improves measurement of symptom pro-
gression. We show that the APOE ε4 allele drives
progressive cognitive impairment in PD. Replication of
this method and results in independent cohorts are
needed. © 2020 The Authors. Movement Disorders publi-
shed by Wiley Periodicals LLC. on behalf of International
Parkinson and Movement Disorder Society
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Progression in Parkinson’s disease (PD) is heteroge-
neous, with some patients progressing rapidly, whereas
others remain relatively stable over time.1 There is a
clear need to identify genetic variants that affect symp-
tom progression in PD. These genes and pathways
could be targeted to develop therapies to stop or slow
the progression of PD. Genetic factors could also help
to stratify patients and predict progression more accu-
rately in clinical trials.
Genome-wide association studies (GWASs) in PD
have identified 90 independent loci associated with dis-
ease risk.2 However, the majority of PD GWASs have
compared cases with healthy controls to identify vari-
ants linked to disease status. To identify variants that
are associated with disease progression, it is necessary
to compare phenotypes within patients.
Progression of clinical signs in PD can be measured in
different ways,3 and there is no gold standard measure
of progression, although the Movement Disorder
Society Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) part III and part II are commonly used in clini-
cal trials. Individual scales, including the MDS-UPDRS,
are affected by measurement error, particularly for
change over time,4 including rater subjectivity and prac-
tice effects in cognitive assessments. Therefore, combin-
ing multiple measures may improve the accuracy of
measuring progression,5,6 as shown in the Huntington’s
disease (HD) progression GWAS.7 In this study, we
analyzed data from 3 large prospective longitudinal
studies: Tracking Parkinson’s, Oxford Parkinson’s Dis-
ease Centre Discovery, and Parkinson’s Progression
Markers Initiative (PPMI). We combined multiple mea-
sures of motor and cognitive progression using princi-
pal components analysis (PCA) to create progression
scores. These scores were analyzed in GWASs to iden-
tify variants associated with composite (cross-domain),
motor, and cognitive progression in PD.
Methods
Standard quality control procedures were performed in
PLINK v1.9. The cohorts were genotyped, filtered, and
imputed separately, but following the same quality con-
trol steps. Only variants with minor allele frequency > 1%
were included. The 3 data sets were merged after
imputation, with only shared variants retained. Genetic
principal components were generated and outliers
removed (see Supplementary Methods and Figs. 1 and 2).
Clinical Outcome Measures
Individual-level data from the cohorts were merged.
To increase the power and the accuracy of the final pro-
gression scores, we performed all transformations and
created progression scores from the merged data set as
follows (Fig. 1).
Motor progression was assessed using MDS-UPDRS
part III (clinician-assessed movement examination), MDS-
UPDRS part II (patient-reported experiences of daily
living), and Hoehn and Yahr stage (clinician-assessed rat-
ing of impairment and disability).8,9 In PPMI, we used
motor assessments conducted in the “off” medication
state.
Cognitive progression was assessed using the Mon-
treal Cognitive Assessment, semantic fluency, and item
1.1 of the MDS-UPDRS (cognitive impairment based
on patient and/or caregiver report).
Raw scores were transformed into percentages and stan-
dardized to the population baseline mean and standard
deviation within each cohort (Supplementary Methods).
Analysis
Progression Scores
We derived severity scores from mixed-effects regression
models using follow-up data up to 72 months. Each vari-
able was regressed on age at onset, sex, cohort, and their
interactions with time from disease onset. PD onset was
based on participants’ self-reported symptom onset. For
the cognitive measures, we included the number of years
of education before higher education and whether higher
education was undertaken as covariates. We included
terms for subject random effects to account for individual
heterogeneity in the intercept (baseline value) and slope
(rate of progression).
We used random-effect slope values as the measure
of “residual” progression not predicted by age at onset,
cohort, sex, and education, for each individual. We per-
formed PCA on these values after zero centering and
scaling to have unit variance. The final progression
scores from the PCA relate to the variability explained,
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and therefore the direction cannot be strictly inter-
preted. Patients who were missing clinical data (eg.
MDS-UPDRS part III total) at all visits were not
included in the PCA and subsequent GWAS analysis.
Removal of Non-PD Cases
Any patients who were diagnosed with a different con-
dition during follow-up were removed from analyses. We
also conducted sensitivity analyses to remove any cases
that may have non-PD conditions but an alternative diag-
nosis had not yet been confirmed. First, we removed
patients in Tracking Parkinson’s and Oxford Discovery
who had a clinician-rated diagnostic certainty of PD
< 90%.10,11 Second, we removed the fastest and slowest
progressors in the top and bottom 5% of the distribution
to address the possibility of confounding by misdiagnosis
with more benign (eg, essential tremor) or more malig-
nant (eg, multiple system atrophy) conditions.
GWAS
For each GWAS, we included the following
covariates: cohort (to adjust for differences in
genotyping data and measurement error) and the first
5 genetic principal components from the merged geno-
type data (to adjust for population substructure).
GWASs were conducted in rvtests12 using the single-
variant Wald test. Genome-wide complex trait analysis
conditional and joint analysis (GCTA-COJO) was used
to identify independent signals.13,14 Individuals carrying
rare variants in GBA, LRRK2, or other PD genes were
not excluded from the GWASs. We also performed sex-
stratified analysis to identify if there are different
genetic associations in men and women.
Genetic risk scores were calculated from the 90 loci
from the PD case–control GWAS,2 and we analyzed the
association with each progression score using linear
regression.
GBA
We analyzed GBA rare variant carriers compared
with noncarriers in a subset of patients, using Sanger
sequencing data from Tracking Parkinson’s and whole-
genome sequencing data from PPMI. In PPMI, only the
following GBA variants were covered: N370S, T369M,
E326K, and R463C. We classified patients as carrying
a pathogenic GBA variant, including Gaucher’s disease
variants and variants associated with PD but excluding
novel variants, using previous studies.15,16 We analyzed
GBA status in relation to the progression scores using
linear regression, adjusting for cohort and the first
5 genetic principal components.
Levodopa-Equivalent Daily Dose-Adjusted
Sensitivity Analyses
Medication may affect MDS-UPDRS part III scores,
in particular in Tracking Parkinson’s and Oxford
FIG. 1. Steps to create composite, motor, and cognitive progression scores. AAO, age at onset. [Color figure can be viewed at wileyonlinelibrary.com]
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Discovery, in which patients were assessed in the “on”
state. To address this, we performed a sensitivity analy-
sis adjusting for levodopa-equivalent daily dose
(LEDD), as described in a previous study, in which we
estimated the effect of levodopa on MDS-UPDRS part
III scores11 (Supplementary Methods). Merely adjusting
for treatment as a covariate is not adequate, as therapy
is not a simple confounder but a direct outcome of the
underlying symptom — individuals who have more
severe symptoms are more likely to be treated17 and
most likely with higher doses.
Results
We included clinical data for 3364 PD patients with
12,144 observations (Table 1). Mean follow-up time ±
SD was 4.2 ± 1.5 years, and mean disease duration at
study entry was 2.9 ± 2.6 years. A total of 79.7% of
patients had completed the 72-month follow-up visit.
Within the motor progression PCA, the first principal
component explained 61.0% of the total variance.
Within the cognitive domain PCA, the first principal
component explained 59.8% of the total variance
(Figs. S3–S6).
We found that the first principal components for
motor and cognitive progression were moderately cor-
related (r = −0.35, P < 2.2 × 10−16; Table S1). We
therefore conducted a PCA combining all motor and
cognitive measures to create a composite progression
score. The first principal component from this cross-
domain PCA accounted for 41.0% of the joint variance
(Figs. S7 and S8). Tables S2–S6 show how the raw
scales and the motor, cognitive, and composite princi-
pal components are correlated. None of the principal
components were associated with cohort (all Ps > 0.9).
GWAS of Composite Progression
After quality control, imputation, and merging,
5,918,868 variants were available for analysis. A total
of 2755 PD patients had composite progression scores
and passed genetic quality control. All GWAS lambdas
were <1.05. One variant, rs429358, in chromosome
19 passed genome-wide significance (P = 1.2 × 10−8;
Fig. 2, Table S7, Figs. S9 and S10). This variant tags
the APOE ε4 allele. In the gene-based test, APOE,
TOMM40, and APOC1 reached significance
(P < 2.8 × 10−6, correcting for the number of mapped
protein coding genes). When we performed conditional
analysis on the top single-nucleotide polymorphism
(SNP), rs429358, there were no other SNPs that passed
significance in this region (Fig. S11). The Reactome
pathway cytosolic sulfonation of the small-molecule
pathway was significantly enriched (P = 6.9 × 10−6).
GWAS of Motor Progression
A total of 2848 PD patients had motor progression
scores and genotype data. No variants passed genome-
wide significance (Fig. 3, Table S8). However, in the
gene-based test, ATP8B2 in chromosome 1 was associ-
ated with motor progression (P = 5.3 × 10−6;
Figs. S12 and S13), although this did not reach signifi-
cance correcting for the number of mapped genes
(P = 2.81 × 10−6).
We conducted follow-up GWASs in each cohort sep-
arately (Table S9) and each motor scale separately
(without combining in PCA) to confirm that the results
were not driven by a single cohort or a single scale.
These results show that associations are strengthened
with the PCA approach (Table S10).
Our top variant in chromosome 1, rs35950207, was
associated with motor progression, P = 5.0 × 10−6. We
examined the associations for this SNP in the previous
progression GWAS18 (https://pdgenetics.shinyapps.io/
pdprogmetagwasbrowser/); rs35950207 was not signifi-
cantly associated with binomial analysis of Hoehn and
Yahr stage 3 or more at baseline (beta = 0.27, P = 0.03).
The variant rs35950207 is 2 kb upstream of AQP10.
It is an expression quantitative trait loci (eQTL) for
AQP10 in whole blood (GTEx, P = 1.7 × 10−6;
eQTLGen, P = 3.62 × 10−139) and other tissues (subcu-
taneous adipose, skin, esophagus, testis, and heart). It is
also an eQTL for ATP8B2 in blood (GTEx,
P = 1.5 × 10−5; eQTLGen, P = 7.84 × 10−42) and in the
cerebellum (GTEx, P = 7.8 × 10−5). GBA is also
located in chromosome 1, and GBA variants are associ-
ated with both PD risk and progression.19 However,
rs35950207 is not in linkage disequilibrium with any
of the main GBA variants that are implicated in PD
(p.E326K, p.N370S, p.L444P, p.T369M).
In chromosome 5, the top SNP in the variant-based
analysis was rs17367669, but there were no genes in
this region that approached significance in the gene-
based analysis. This variant is closest to
LOC100505841, zinc finger protein 474-like gene. No
significant eQTLs were identified for this variant.
GWAS of Cognitive Progression
A total of 2788 patients had cognitive progression
scores and genotype data. The top variant was
rs429358, which tags the APOE ε4 allele
(P = 2.53 × 10−13; Fig. 4, Table S11, Figs. S14 and
S15). Figure S16 shows that ε4 carriers had more severe
cognitive progression. APOE was also significantly
associated with cognitive progression in the gene-based
analysis, in addition to APOC1 and TOMM40.
Follow-up analyses showed that the effects for the top
5 independent SNPs were consistent in each cohort and
each scale (Tables S12 and S13).
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When we performed conditional analysis on the
top SNP, rs429358, a group of SNPs still passed
genome-wide significance, indicating independent
signals (Fig. S17). The top SNP was rs6857
(beta = −0.33, P = 4.4 × 10−11). This is a 30 UTR
variant in NECTIN2. We also conditioned on the
other APOE SNP, rs7412, in addition to rs429358
(if both rs429358 and rs7412 harbor the C alleles,
then this codes the ε4 allele). This did not change
the results.
When conditioning on both rs429358 and rs6857,
there were still several SNPs that passed significance,
the top being rs12721051, an intronic variant in
APOC1.
TABLE 1. Cohort demographics at baseline
Demographics at baseline Tracking Parkinson’s Oxford Discovery PPMI ALL
Number of PD patients 1966 985 413 3364
Total number of visits analyzed 5936 3142 3066 12,144
Mean length of follow-up (years) 3.8 (1.4) 4.3 (1.7) 5.4 (1.2) 4.2 (1.5)
Male (%) 65.2% 64.2% 65.4% 65.0%
Age at onset (years) 64.4 (9.8) 64.5 (9.8) 59.5 (10.0) 63.9 (10.0)
Age at diagnosis (years) 66.3 (9.3) 66.1 (9.6) 61.0 (9.7) 65.6 (9.6)
Age at study entry (years) 67.6 (9.3) 67.4 (9.6) 61.5 (9.8) 66.8 (9.7)
Disease duration — time from symptom onset to
assessment (years)
3.2 (3.0) 2.9 (1.9) 2.0 (2.0) 2.9 (2.6)
Time from diagnosis to assessment (years) 1.3 (0.9) 1.3 (0.9) 0.5 (0.5) 1.2 (0.9)
MDS-UPDRS part III 22.9 (12.3) 26.8 (11.1) 20.7 (8.8) 23.8 (11.7)
MDS-UPDRS part III annual changea 1.9 (3.7) 2.1 (3.5) 1.8 (2.2) 2.1 (6.2)
MDS-UPDRS part II 9.9 (6.6) 8.9 (6.2) 5.8 (4.1) 9.0 (6.3)
MDS-UPDRS part II annual changea 1.3 (1.6) 1.3 (1.6) 0.9 (1.1) 1.3 (2.8)
Hoehn and Yahr stage meanb 1.8 (0.6) 1.9 (0.6) 1.6 (0.5) 1.8 (0.6)
Hoehn and Yahr stage annual change 0.1 (0.2) 0.06 (0.1) 0.08 (0.1) 0.06 (0.3)
Hoehn and Yahr stage 0 to 1.5 (%) 48.1% 23.2% 44.8% 40.4%
Hoehn and Yahr stage 2 to 2.5 (%) 45.1% 68.8% 54.7% 53.2%
Hoehn and Yahr stage 3c (%) 6.8% 8.1% 0.5% 6.4%
MoCA total (adjusted for education) 24.9 (3.6) 24.5 (3.5) 27.1 (2.3) 25.0 (3.6)
MoCA total annual change −0.1 (0.9) −0.1 (0.8) −0.2 (0.6) −0.1 (1.5)
Semantic fluencyc 21.8 (6.9) 34.7 (9.0) 21.0 (5.4) 25.5 (9.5)
Semantic fluency annual change −0.2 (1.5) −0.5 (2.0) −0.1 (0.9) −0.5 (3.0)
MDS-UPDRS part I.1 0.5 (0.7) 0.5 (0.6) 0.3 (0.5) 0.5 (0.7)
MDS-UPDRS part I.1 annual change 0.07 (0.2) 0.05 (0.2) 0.07 (0.1) 0.05 (0.3)
SD, standard deviation; PPMI, Parkinson’s Progression Markers Initiative; PD, Parkinson’s disease; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s
Disease Rating Scale; MoCA, Montreal Cognitive Assessment. Mean (SD) shown unless otherwise indicated.
aAnnual change score derived from a mixed-effects model of the raw scores as a function of years from onset, with subject random effects to account for individ-
ual heterogeneity in the intercept (baseline values) and slope (rate of progression). No other covariates were included in the model within each cohort. For the
overall value, we adjusted for cohort and the interaction between cohort and years from onset.
bTracking Parkinson’s used the modified Hoehn and Yahr stage scale, whereas Oxford Discovery and PPMI used the original scale. Hoehn and Yahr stage pro-
portions are shown as a total of the number of people with nonmissing Hoehn and Yahr ratings at baseline.
cInstructions and timing for the semantic fluency task were slightly different between cohorts (completed within 60 or 90 seconds). To account for these differ-
ences, we standardized all scales within each cohort separately (see Methods section).
FIG. 2. Manhattan plot for GWAS of composite progression. The red dashed line indicates the genome-wide significance threshold, P = 5 × 10−8. The
top genes from the MAGMA gene-based analysis and P values are shown on the right. [Color figure can be viewed at wileyonlinelibrary.com]
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We found frequencies of APOE genotypes similar to
those of previous studies20 (Table S14).
LEDD-Adjusted Analyses
When we performed GWASs of composite progres-
sion and motor progression after adjusting for LEDD,
we did not find substantial differences. No SNPs passed
genome-wide significance. The top SNP for composite
progression was still rs429358, and this was in the
same direction and similar effect size as in the main
analysis (beta = 0.33, P = 8.8 × 10−8). For motor pro-
gression, the top SNP was also the same as in the main
analysis and ATP8B2 and AQP10 still the top genes in
the MAGMA gene analysis, although not genome-wide
significant.
Sex-Stratified Analyses
The APOE locus passed genome-wide significance
only in men for composite progression and cognitive
progression (P < 5 × 10−8). Other than this locus, there
were no SNPs that passed significance. These analyses
are underpowered, and sex differences need to be inves-
tigated in more detail.
Targeted Assessment of PD Risk Loci
Of the 90 risk variants from the PD case–control
GWAS,2 73 were present in our final data set, including
the SNCA and TMEM175/GAK variants associated
with PD age at onset.21 No variants passed analysis-
wide significance (P = 0.05/73). Variants with at least 1
association, P < 0.05, are shown in Figure S18.
We found that only a small number of risk variants
were associated with progression, with P < 0.05. The
variant rs35749011 was associated with both compos-
ite progression (beta = 0.40, P = 0.003) and cognitive
progression (beta = −0.37, P = 0.002), but not motor
progression (beta = 0.20, P = 0.09). This variant is in
linkage disequilibrium with the GBA p.E326K variant
(also known as p.E365K), D0 = 0.90, R2 = 0.78.
We also extracted results for other candidate variants
that have been implicated in PD progression (Fig. S19).
We did not find that the top variant, rs382940, in
SLC44A1 that was associated in progression to Hoehn
and Yahr stage 3 from the Iwaki GWAS18 was
FIG. 3. Manhattan plot for the GWAS of motor progression. Genome-wide significance is the standard P = 5 × 10−8 (not indicated in the figure). The
top genes from the MAGMA gene-based analysis and P values are shown on the right. [Color figure can be viewed at wileyonlinelibrary.com]
FIG. 4. Manhattan plot for the variant-based GWAS of cognitive progression. The red dashed line indicates the genome-wide significance threshold, P
= 5 × 10−8. The top genes from the MAGMA gene-based analysis and P values are shown on the right. [Color figure can be viewed at
wileyonlinelibrary.com]
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associated with either composite, motor, or cognitive
progression in our GWASs.
Overall, we did not find any overlap between the var-
iants associated with PD risk, age at onset, and progres-
sion. Our Linkage Disequilibrium Score Regression
(LDSC) results also suggested very little overlap
between each of the progression GWASs and PD case–
control GWAS (all Ps > 0.5).
PD Genetic Risk Score
A total of 73 PD risk SNPs were present in our geno-
type data, and 2 proxies were identified for missing var-
iants (Table S15). The risk score was nominally
associated with cognitive progression (beta = −0.098,
P = 0.04) but not composite (beta = 0.09, p=0.12) or
motor progression (beta = 0.02, P = 0.69).
GBA
GBA data was available for 2020 patients from
Tracking Parkinson’s and PPMI. 194 (9.6%) carried
a pathogenic variant in GBA (Table S16). GBA sta-
tus was significantly associated with composite pro-
gression (beta = 0.40, P = 0.001) and cognitive
progression (beta = −0.35, P = 0.0008), but not
motor progression (beta = 0.18, P = 0.10).
Removal of Potential Non-PD Cases
Removing patients with <90% diagnostic certainty
did not substantially affect our results; the top signals
had slightly weaker associations in these sensitivity ana-
lyses. When we removed the extreme 5% of pro-
gressors, the top results from the main GWASs had the
larger P values, although the direction of effects were
the same (Tables S17 and S18).
Discussion
We used a new method of analyzing clinical progres-
sion in PD by combining multiple assessments in a
data-driven PCA to derive scores of composite, motor,
and cognitive progression in large clinical cohorts.
Our study contributes to evidence that improving the
phenotypic measure can increase power in genetic stud-
ies. We showed that associations at the top signals
strengthened when using the combined motor and cog-
nitive progression scores compared with using the
scales separately. The HD progression GWAS also
showed that motor, cognitive, and brain imaging mea-
sures were well correlated and successfully identified a
variant in MSH3 associated with composite progres-
sion.7 Other studies show prediction accuracy of PD
status or progression (such as development of cognitive
impairment) is improved by combining multiple clini-
cal, genetic, and biomarker factors.6,22
In PD, there are many different scales for assessing
symptoms. Each scale has a degree of measurement
error4 and different sensitivity to progression of under-
lying symptoms.23 PCA is a data-driven approach that
combines multiple measures to identify latent compo-
nents that explain the most variability in the data, and
these may more accurately reflect disease progression.
Our progression GWASs have 2 main findings. First,
we replicated previous findings for APOE ε4. Many
studies have shown that the ε4 allele is associated with
dementia in PD,20,24–26 and potentially separately from
the risk of Alzheimer’s disease (AD).27 One possible
mechanism is that APOE is associated with amyloid-β
pathology, as comorbid AD pathology is common in
PD patients with dementia (PDD) at postmortem.28
Alternatively, APOE may drive cognitive decline inde-
pendently of amyloid/AD pathology. Recent animal
model work has shown that the ε4 allele is indepen-
dently associated with α-synuclein pathology and toxic-
ity.29 In addition, the ε4 allele is overrepresented in
dementia with Lewy body cases with “pure” Lewy
body pathology, compared with PDD cases.30 A sys-
tematic review showed that limbic and neocortical
α-synuclein pathology had the strongest association
with PD dementia.28 Further work is needed to deter-
mine the mechanisms by which APOE influences cogni-
tive decline.
In the APOE locus, there may be multiple indepen-
dent signals for cognitive progression. This is similar to
AD, in which multiple risk loci have been located in
chromosome 19 in addition to APOE, including
TOMM40, APOC1, and more distant genes. This
study was not powered to conduct analyses stratified
by APOE genotype, as has been done in AD.31 Further
work is needed to fine-map this region and determine if
there are other genes that contribute to cognitive
progression.
We identified a novel signal in ATP8B2 associated
with motor progression in a gene-based analysis. This
gene encodes an ATPase phospholipid transporter (type
8B, member 2). Phospholipid translocation may be
important in the formation of transport vesicles.32 This
gene has not been reported in PD or other diseases and
needs to be tested in other cohorts.
Our sensitivity analysis adjusting for LEDD suggests
that levodopa may influence the absolute scores in the
MDS-UPDRS part III but does not influence the rate of
progression, and this was shown in a previous study.33
We also found that the mean rate of change in MDS-
UPDRS part III was comparable in Tracking
Parkinson’s/Oxford Discovery and PPMI (Table 1),
despite the different medication states. Together, these
suggest that medication has not influenced our results
for motor progression.
We have shown that the genetics of PD risk and pro-
gression are largely separate. In our targeted analysis of
Movement Disorders, 2020 7
P D P R O G R E S S I O N G W A S
PD risk variants, GBA p.E326K was nominally associ-
ated with composite and cognitive progression. Analy-
sis of sequencing data showed that GBA status was
strongly associated with composite and cognitive pro-
gression, but not motor progression. Previous studies
show that GBA variants are associated with rapid pro-
gression and mortality34–39; however, many of these
studies have longer follow-up or patients with longer
disease duration. This may explain why we did not find
a strong effect for motor progression and is supported
by analysis of GBA in patients at an earlier stage of the
disease.15 In addition, previous studies have used differ-
ent methods to measure progression. Our unbiased
genome-wide search suggests that, in addition to GBA,
there are potentially other genes that are important for
PD progression.
Our targeted analysis showed that only a few PD risk
variants were nominally associated with progression,
similar to the previous PD progression GWAS.18,40 This
suggests that there is minimal overlap in the genetic
architecture of PD risk and PD progression. Similarly,
the age at onset GWAS showed only a partial overlap
with the genetics of PD risk.21 We now have the ability
to study progression through the integration of detailed
clinical data with genome-wide genetic variation in
large-scale studies, and this can improve our under-
standing of the biology of progression.
We did not replicate the finding for the SLC44A1
variant that was associated with progression to Hoehn
and Yahr stage 3 in a previous PD progression
GWAS.18 We have used different methods and a differ-
ent phenotype to analyze PD progression. Further pro-
gression GWASs are needed to replicate both sets of
results, and other metrics for PD progression could be
analyzed, such as mortality.
Although no other large genome-wide GWASs have
investigated PD progression, many candidate gene stud-
ies have nominated common genetic factors associated
with progression. Aside from APOE, common variants
in MAPT,1,41–43 COMT,24,42 BDNF, MTHFR, and
SORL144 have been reported to influence cognitive
decline (reviewed in Fagan and Pihlstrom45). For motor
progression, other than GBA, common variants in
SNCA have been suggested to influence the rate of
decline, although these studies are small and have not
been confirmed in large studies.26,46–49 A small GWAS
of motor and cognitive progression identified suggestive
loci in C8orf4 and CLRN3,50 although these have not
been replicated. A novel machine-learning approach
found that variation in LINGO2 was associated with
change in the MDS-UPDRS,51 although again this find-
ing needs independent replication. We did not replicate
these findings, possibly because we were underpowered
as a GWAS to detect variants with smaller effects or
because we have analyzed progression using different
methods. However, many of these previous studies are
small, and some associations have not been convinc-
ingly replicated.
Our study has some limitations. Follow-up was lim-
ited to 72 months, and longer follow-up is needed to
detect variants that may influence progression in later
disease stages, such as GBA.
We may also be underpowered to detect variants
with smaller effects on progression. Although the HD
GWAS identified significant signals in smaller samples,7
analysis of PD progression is more complex because of
slower progression, greater heterogeneity in genetic risk
and rate of progression between patients, and greater
dissociation between motor and cognitive progression.
Our findings need to be tested in independent cohorts,
and the lack of independent replication is another limi-
tation of this study.
A third limitation is that symptom progression may
be influenced by non-SNP variants (such as rare vari-
ants or structural variants) and gene–gene interactions
that would be missed by GWASs, or environmental fac-
tors and comorbidities.
A final limitation is the potential inclusion of patients
that have non-PD conditions. We did not find that our
results changed substantially when we excluded
patients with diagnostic certainty < 90%. However,
certainty data were not available for PPMI, and abnor-
mal dopamine transporter scans cannot differentiate
between PD and other degenerative parkinsonian con-
ditions.52 Despite this, our sensitivity analysis suggest
that our results are not being driven by non-PD condi-
tions. Our GWASs also did not identify loci that are
associated with PSP risk, including MAPT, MOBP,53
or rs2242367 near LRRK2 associated with PSP
progression.54
Many of our top variants had weaker signals when
we excluded the fastest- and slowest-progressing
patients. With our duration of follow-up, we should
have excluded the majority of non-PD patients, as diag-
nostic accuracy improves after 5-year duration of dis-
ease1,55; however, it is possible that some have not been
excluded. Analysis of pathologically confirmed PD
cases is needed to resolve this issue. Alternatively, this
may indicate that genotypes have different effects in the
most extreme progressors. This could be because of
comorbidities such as vascular burden56 or interactions
between synuclein and copathologies (such as amyloid,
and tau)57,58 in the rapid progressors that exacerbates
clinical progression.
This study is the first to use a PCA data reduction
method to assess PD progression, based on a successful
approach in HD. We robustly replicated the association
between APOE ε4 and cognitive progression and have
identified other genes that may be important. These
advances are essential to understanding the biology of
disease progression and nominating therapeutic targets
to stop or slow PD progression.
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